Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Hematologic Diseases"
Show Display Options
Rank Status Study
1 Recruiting Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia
Conditions: Hematologic Malignancies;   Hypoproliferative Thrombocytopenia
Interventions: Device: Mirasol platelets (MIR PLTs);   Device: Reference platelets (REF PLTs)
2 Recruiting Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Conditions: Blood Coagulation Disorders;   Hemorrhage
Intervention: Biological: Fresh frozen plasma transfusion
3 Recruiting Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Conditions: Leukemia;   Leukemia,Pediatric;   Leukemia, Myleiod;   Leukemia, Mylegenous, Chronic;   Leukemia, Mylegenous, Accelerated;   BCR-ABL Positive;   Myeloproliferative Disorder;   Bone Marrow Disease;   Hematologic Diseases;   Neoplastic Processes;   Imatinib;   Dasatinib;   Enzyme Inhibitor;   Protein Kinase Inhibitor
Intervention: Drug: nilotinib
4 Recruiting Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
Condition: Anemia, Sickle Cell
Interventions: Drug: Rivipansel;   Other: Placebo
5 Recruiting Study of Blood Samples From Newborns With Down Syndrome
Condition: Leukemia
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
6 Recruiting Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Conditions: Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Penile Carcinoma;   Renal Pelvis Urothelial Carcinoma;   Squamous Cell Carcinoma of the Penis;   Stage III Bladder Adenocarcinoma;   Stage III Bladder Squamous Cell Carcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage III Penile Cancer;   Stage III Renal Cell Cancer;   Stage III Renal Pelvis Carcinoma;   Stage III Ureter Cancer;   Stage III Urethral Cancer;   Stage IIIa Penile Cancer;   Stage IIIb Penile Cancer;   Stage IV Bladder Adenocarcinoma;   Stage IV Bladder Squamous Cell Carcinoma;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Penile Cancer;   Stage IV Renal Cell Cancer;   Stage IV Renal Pelvis Carcinoma;   Stage IV Ureter Cancer;   Stage IV Urethral Cancer;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
7 Recruiting Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
8 Recruiting Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Conditions: Myelodysplastic Syndrome;   MDS;   Refractory Anemia With Excess Blasts;   RAEB
Interventions: Drug: rigosertib;   Drug: Any approved or standard-of-care therapy;   Drug: best supportive care (BSC)
9 Recruiting An Investigational Immuno-therapy Study of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Elotuzumab;   Drug: Pomalidomide;   Drug: Dexamethasone
10 Available Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Daratumumab
11 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
12 Recruiting Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Conditions: Multiple Myeloma;   Lymphoma, Large B-Cell, Diffuse;   Pleiotropic Pathway Modifier;   Glioblastoma;   Lymphoma;   Primary Central Nervous System Lymphoma
Intervention: Drug: CC-122
13 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
14 Recruiting Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Conditions: Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
15 Recruiting Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
Condition: Immune Thrombocytopenic Purpura
Intervention: Drug: BMS-986004

Study has passed its completion date and status has not been verified in more than two years.